用于卵巢肿瘤免疫闪烁显像检测的单克隆抗体MAb-170。

Monoclonal antibody MAb-170 for immunoscintigraphic detection of ovarian tumors.

作者信息

Alexander C, Villena-Heinsen C E, Schaefer A, Toth L, Schmidt W, Kirsch C M

机构信息

Department of Nuclear Medicine, Saarland University Medical Center, Homburg, Germany.

出版信息

Am J Obstet Gynecol. 1999 Sep;181(3):513-7. doi: 10.1016/s0002-9378(99)70485-0.

DOI:10.1016/s0002-9378(99)70485-0

PMID:10486456

Abstract

OBJECTIVE

The technetium Tc 99m-labeled monoclonal antibody MAb-170 was designed for diagnostic use in patients with gynecologic adenocarcinoma. Our investigation was initiated to verify its usefulness for radioimmunoscintigraphy of ovarian tumors.

STUDY DESIGN

Most of the 82 patients participating in this study underwent immunoscintigraphy before first-look surgery.

RESULTS

Radioimmunoscintigraphy recognized 36 of 41 patients with adenocarcinoma of the ovaries, corresponding to an overall sensitivity of 88%. Specificity was 90% (38/42). The calculation of accuracy gave a result of 89% (74/83). Of 110 known lesions, 92 were visualized successfully; thus the local-regional sensitivity was 84%. Of 160 benign tumor sites, 154 showed no evidence of tracer accumulation, corresponding to a local-regional specificity of 96%. The smallest lesion visualized was an adenocarcinoma of the corpus uteri with a diameter of 1.5 cm.

CONCLUSION

The monoclonal antibody MAb-170 is a promising radiopharmaceutical for immunoscintigraphy of ovarian adenocarcinoma.

摘要

目的

锝 Tc 99m 标记的单克隆抗体 MAb - 170 设计用于妇科腺癌患者的诊断。我们开展此项研究以验证其在卵巢肿瘤放射免疫闪烁成像中的效用。

研究设计

参与本研究的 82 例患者中，大多数在初次探查手术前接受了免疫闪烁成像检查。

结果

放射免疫闪烁成像识别出 41 例卵巢腺癌患者中的 36 例，总体敏感性为 88%。特异性为 90%（38/42）。准确性计算结果为 89%（74/83）。在 110 个已知病变中，92 个成功显影；因此局部区域敏感性为 84%。在 160 个良性肿瘤部位中，154 个未显示示踪剂积聚迹象，局部区域特异性为 96%。显影的最小病变是一例直径为 1.5 cm 的子宫体腺癌。